Research progress of triglyceride glucose-body mass index

LI Yanian; HE Shenghu

doi:10.7619/jcmp.20213765

Journal of Clinical Medicine in Practice > 2022 > 26(9): 130-133. > DOI: 10.7619/jcmp.20213765

LI Yanian, HE Shenghu. Research progress of triglyceride glucose-body mass index[J]. Journal of Clinical Medicine in Practice, 2022, 26(9): 130-133. DOI: 10.7619/jcmp.20213765

Citation:

LI Yanian, HE Shenghu. Research progress of triglyceride glucose-body mass index[J]. Journal of Clinical Medicine in Practice, 2022, 26(9): 130-133. DOI: 10.7619/jcmp.20213765

Citation:

LI Yanian, HE Shenghu. Research progress of triglyceride glucose-body mass index[J]. Journal of Clinical Medicine in Practice, 2022, 26(9): 130-133. DOI: 10.7619/jcmp.20213765

PDF (607 KB)

Research progress of triglyceride glucose-body mass index

LI Yanian¹,
HE Shenghu^2, ,

1.
Graduate School of Dalian Medical University, Dalian, Liaoning, 116044
2.
Department of Cardiovascular Medicine, Subei People's Hospital of Jiangsu Province, Yangzhou, Jiangsu, 225001

More Information

Received Date: September 17, 2021
Available Online: May 09, 2022
Published Date: May 14, 2022

Graphical Abstract

Abstract

Abstract

Insulin resistance (IR) is one of the important factors affecting cardiovascular diseases and various metabolic diseases. It is very important to identify IR before the disease occurs. Triglyceride glucose-body mass (TyG-BMI) index is a new economic and effective index for evaluating IR. In recent years, the role of TyG-BMI in the evaluation of atherosclerosis, prehypertension, prediabetes, hyperuricemia, non-alcoholic fatty liver disease and other common clinical diseases has been confirmed to some extent, and it has become a new research direction. However, there are still few studies on TyG-BMI at home and abroad, and the specific mechanism remains unclear and needs further exploration. This paper reviewed the research progress of TyG-BMI and its relationship with common diseases, in order to provide positive guidance for the early prevention.
- triglyceride glucose-body mass index,
- insulin resistance,
- cardiovascular disease,
- metabolic disease

FullText(HTML)

References (42)

References

[1]	《中国心血管健康与疾病报告2020》编写组. 《中国心血管健康与疾病报告2020》概述[J]. 中国心血管病研究, 2021, 19(7): 582-590. doi: 10.3969/j.issn.1672-5301.2021.07.002
[2]	WANG Z W, CHEN Z, ZHANG L F, et al. Status of hypertension in China: results from the China hypertension survey, 2012-2015[J]. Circulation, 2018, 137(22): 2344-2356. doi: 10.1161/CIRCULATIONAHA.117.032380
[3]	WANG L M, ZHOU B, ZHAO Z P, et al. Body-mass index and obesity in urban and rural China: findings from consecutive nationally representative surveys during 2004-18[J]. Lancet, 2021, 398(10294): 53-63. doi: 10.1016/S0140-6736(21)00798-4
[4]	XIA C, LI R, ZHANG S, et al. Lipid accumulation product is a powerful index for recognizing insulin resistance in non-diabetic individuals[J]. Eur J Clin Nutr, 2012, 66(9): 1035-1038. doi: 10.1038/ejcn.2012.83
[5]	CHENG Y H, TSAO Y C, TZENG I S, et al. Body mass index and waist circumference are better predictors of insulin resistance than total body fat percentage in middle-aged and elderly Taiwanese[J]. Medicine (Baltimore), 2017, 96(39): e8126. doi: 10.1097/MD.0000000000008126
[6]	GAST K B, TJEERDEMA N, STIJNEN T, et al. Insulin resistance and risk of incident cardiovascular events in adults without diabetes: meta-analysis[J]. PLoS One, 2012, 7(12): e52036. doi: 10.1371/journal.pone.0052036
[7]	ER L K, WU S, CHOU H H, et al. Triglyceride glucose-body mass index is a simple and clinically useful surrogate marker for insulin resistance in nondiabetic individuals[J]. PLoS One, 2016, 11(3): e0149731. doi: 10.1371/journal.pone.0149731
[8]	LILLIOJA S, MOTT D M, SPRAUL M, et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians[J]. N Engl J Med, 1993, 329(27): 1988-1992. doi: 10.1056/NEJM199312303292703
[9]	MINH H V, TIEN H A, SINH C T, et al. Assessment of preferred methods to measure insulin resistance in Asian patients with hypertension[J]. J Clin Hypertens (Greenwich), 2021, 23(3): 529-537. doi: 10.1111/jch.14155
[10]	SÁNCHEZ-GARCÍA A, RODRÍGUEZ-GUTIÉRREZ R, MANCILLAS-ADAME L, et al. Diagnostic accuracy of the triglyceride and glucose index for insulin resistance: a systematic review[J]. Int J Endocrinol, 2020, 2020: 4678526.
[11]	BALA C, GHEORGHE-FRONEA O, POP D, et al. The association between six surrogate insulin resistance indexes and hypertension: a population-based study[J]. Metab Syndr Relat Disord, 2019, 17(6): 328-333. doi: 10.1089/met.2018.0122
[12]	RAMÍREZ-VÉLEZ R, PÉREZ-SOUSA M Á, GONZÁLEZ-RUÍZ K, et al. Obesity- and lipid-related parameters in the identification of older adults with a high risk of prediabetes according to the American diabetes association: an analysis of the 2015 health, well-being, and aging study[J]. Nutrients, 2019, 11(11): 2654. doi: 10.3390/nu11112654
[13]	LIM J, KIM J, KOO S H, et al. Comparison of triglyceride glucose index, and related parameters to predict insulin resistance in Korean adults: an analysis of the 2007-2010 Korean National Health and Nutrition Examination Survey[J]. PLoS One, 2019, 14(3): e0212963. doi: 10.1371/journal.pone.0212963
[14]	BORNFELDT K E, TABAS I. Insulin resistance, hyperglycemia, and atherosclerosis[J]. Cell Metab, 2011, 14(5): 575-585. doi: 10.1016/j.cmet.2011.07.015
[15]	AN X Q, YU D, ZHANG R Y, et al. Insulin resistance predicts progression of de novo atherosclerotic plaques in patients with coronary heart disease: a one-year follow-up study[J]. Cardiovasc Diabetol, 2012, 11: 71. doi: 10.1186/1475-2840-11-71
[16]	HUANG Y C, HUANG J C, LIN C I, et al. Comparison of innovative and traditional cardiometabolic indices in estimating atherosclerotic cardiovascular disease risk in adults[J]. Diagnostics (Basel), 2021, 11(4): 603. doi: 10.3390/diagnostics11040603
[17]	DU Z, XING L Y, LIN M, et al. Estimate of prevalent ischemic stroke from triglyceride glucose-body mass index in the general population[J]. BMC Cardiovasc Disord, 2020, 20(1): 483. doi: 10.1186/s12872-020-01768-8
[18]	MENG X J, DONG G H, WANG D, et al. Epidemiology of prehypertension and associated risk factors in urban adults from 33 communities in China: the CHPSNE study[J]. Circ J, 2012, 76(4): 900-906. doi: 10.1253/circj.CJ-11-1118
[19]	PAQUISSI F C, MANUEL V, MANUEL A, et al. Prevalence of cardiovascular risk factors among workers at a private tertiary center in Angola[J]. Vasc Health Risk Manag, 2016, 12: 497-503. doi: 10.2147/VHRM.S120735
[20]	AFRIFA-ANANE E, AGYEMANG C, CODJOE S N, et al. The association of physical activity, body mass index and the blood pressure levels among urban poor youth in Accra, Ghana[J]. BMC Public Health, 2015, 15: 269. doi: 10.1186/s12889-015-1546-3
[21]	MANCUSI C, IZZO R, DI GIOIA G, et al. Insulin resistance the hinge between hypertension and type 2 diabetes[J]. High Blood Press Cardiovasc Prev, 2020, 27(6): 515-526. doi: 10.1007/s40292-020-00408-8
[22]	SCHERRER U, RANDIN D, VOLLENWEIDER P, et al. Nitric oxide release accounts for insulin's vascular effects in humans[J]. J Clin Invest, 1994, 94(6): 2511-2515. doi: 10.1172/JCI117621
[23]	STEINBERG H O, CHAKER H, LEAMING R, et al. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance[J]. J Clin Invest, 1996, 97(11): 2601-2610. doi: 10.1172/JCI118709
[24]	FUKUDA N, SATOH C, HU W Y, et al. Endogenous angiotensin Ⅱsuppresses insulin signaling in vascular smooth muscle cells from spontaneously hypertensive rats[J]. J Hypertens, 2001, 19(9): 1651-1658. doi: 10.1097/00004872-200109000-00018
[25]	LEMBO G, NAPOLI R, CAPALDO B, et al. Abnormal sympathetic overactivity evoked by insulin in the skeletal muscle of patients with essential hypertension[J]. J Clin Invest, 1992, 90(1): 24-29. doi: 10.1172/JCI115842
[26]	MASI S, ULIANA M, VIRDIS A. Angiotensin Ⅱ and vascular damage in hypertension: role of oxidative stress and sympathetic activation[J]. Vascul Pharmacol, 2019, 115: 13-17. doi: 10.1016/j.vph.2019.01.004
[27]	TABIT C E, CHUNG W B, HAMBURG N M, et al. Endothelial dysfunction in diabetes mellitus: molecular mechanisms and clinical implications[J]. Rev Endocr Metab Disord, 2010, 11(1): 61-74. doi: 10.1007/s11154-010-9134-4
[28]	ZENG Z Y, LIU S X, XU H, et al. Association of triglyceride glucose index and its combination of obesity indices with prehypertension in lean individuals: a cross-sectional study of Chinese adults[J]. J Clin Hypertens (Greenwich), 2020, 22(6): 1025-1032. doi: 10.1111/jch.13878
[29]	WILSON M L. Prediabetes: beyond the borderline[J]. Nurs Clin North Am, 2017, 52(4): 665-677. doi: 10.1016/j.cnur.2017.07.011
[30]	CHO N H, SHAW J E, KARURANGA S, et al. IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045[J]. Diabetes Res Clin Pract, 2018, 138: 271-281. doi: 10.1016/j.diabres.2018.02.023
[31]	KANBAY M, JENSEN T, SOLAK Y, et al. Uric acid in metabolic syndrome: from an innocent bystander to a central player[J]. Eur J Intern Med, 2016, 29: 3-8. doi: 10.1016/j.ejim.2015.11.026
[32]	HYNDMAN D, LIU S, MINER J N. Urate handling in the human body[J]. Curr Rheumatol Rep, 2016, 18(6): 34. doi: 10.1007/s11926-016-0587-7
[33]	TESTA A, PRUDENTE S, LEONARDIS D, et al. A genetic marker of hyperuricemia predicts cardiovascular events in a meta-analysis of three cohort studies in high risk patients[J]. Nutr Metab Cardiovasc Dis, 2015, 25(12): 1087-1094. doi: 10.1016/j.numecd.2015.08.004
[34]	SAKURAI H. Urate transporters in the genomic era[J]. Curr Opin Nephrol Hypertens, 2013, 22(5): 545-550. doi: 10.1097/MNH.0b013e328363ffc8
[35]	NAKAGAWA T, CIRILLO P, SATO W, et al. The conundrum of hyperuricemia, metabolic syndrome, and renal disease[J]. Intern Emerg Med, 2008, 3(4): 313-318. doi: 10.1007/s11739-008-0141-3
[36]	VADAKEDATH S, KANDI V. Probable potential role of urate transporter genes in the development of metabolic disorders[J]. Cureus, 2018, 10(3): e2382.
[37]	SHI W R, XING L Y, JING L, et al. Usefulness of Triglyceride-glucose Index for estimating Hyperuricemia risk: insights from a general Population[J]. Postgrad Med, 2019, 131(5): 348-356. doi: 10.1080/00325481.2019.1624581
[38]	GU Q, HU X, MENG J, et al. Associations of triglyceride-glucose index and its derivatives with hyperuricemia risk: a cohort study in Chinese general population[J]. Int J Endocrinol, 2020, 2020: 3214716.
[39]	FUJⅡ H, KAWADA N, JAPAN STUDY GROUP OF NAFLD JSG-NAFLD. The role of insulin resistance and diabetes in nonalcoholic fatty liver disease[J]. Int J Mol Sci, 2020, 21(11): 3863. doi: 10.3390/ijms21113863
[40]	ZHANG S J, DU T T, LI M N, et al. Triglyceride glucose-body mass index is effective in identifying nonalcoholic fatty liver disease in nonobese subjects[J]. Medicine (Baltimore), 2017, 96(22): e7041. doi: 10.1097/MD.0000000000007041
[41]	SIMENTAL-MENDÍA L E, SIMENTAL-MENDÍA E, RODRÍGUEZ-HERNÁNDEZ H, et al. The product of triglycerides and glucose as biomarker for screening simple steatosis and NASH in asymptomatic women[J]. Ann Hepatol, 2016, 15(5): 715-720.
[42]	FEDCHUK L, NASCIMBENI F, PAIS R, et al. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease[J]. Aliment Pharmacol Ther, 2014, 40(10): 1209-1222. doi: 10.1111/apt.12963

Cited By

Get Citation

PDF

XML

Article views (517) PDF downloads (108)

Turn off MathJax

Article Contents

Abstract

References

Research progress of triglyceride glucose-body mass index

Abstract

References

Catalog

Export File

Citation

Format

Content